RT @NielsvdSangen: Proud to have presented the #OPTICA study at #TCT2022. Directly omitting aspirin after successful PCI for ACS is feasibl…

RT @aomar_md: Hot off the Press. Grateful to my mentors and team. Special thanks to @georgedangas Meta-Analysis Comparing Fractional Flow R…

Thanks to JACC: Asia for the opportunity to co-author this editorial on residual inflammatory risk and PCI with our star fellow Anna van Veelen. Great original research by Jong-Hwa Ahn et al.!

RT @RCMjournal: #RCM - Vol. 23 No. 1 🩸Review Identification and treatment of the vulnerable coronary plaque #VulnerablePlaque #Atheroscler…

RT @CircIntv: More on de-escalation antiplatelet therapy following #PCI. Does the Chinese population respond differently? TWILIGHT China su…

Hot off the press: everything you always wanted to know about “Identification and Treatment of the Vulnerable Plaque”! @RCMjournal @NielsvdSangen

RT @adrianocaixeta: An honor to be part of the organizing committee of the @PCRonline São Paulo Hub. For the first time this important meet…

@ignamatsant @adnanalkhouli @TCTConference Agreed! Well deserved @adnanalkhouli ! Proud to have been nominated for this award together with (future) giants like you and @ignamatsant !

RT @NatRevCardiol: In a new Review, @FBeerkens @BimmerClaessen @derrickytam @Drroxmehran et al. discuss contemporary CABG surgery and subse…

@BoopathyCardio Congrats Boopathy! Keep up the good work!

RT @JAMACardio: Review of design features and outcomes of various #TAVR devices: There is insufficient evidence to claim superiority of one…

RT @CCIJournal: Updated meta-analysis of 31 trials (n=30,096): #RadialFirst a/w less bleeding, vascular complications, & mortality than fe…

RT @JAHA_AHA: Find out about present and future of best practices regarding evidence-based lipid management after ACS!

Just out: "Considerations for Optimal Device Selection in TAVR" Thanks to: @SaminKSharma @GilbertTangMD & dr Annapoorna Kini! via @JAMACardio part of @JAMANetwork